No Prescription |
 |
 | ||
|
Voltaren Cataflam |
|
| ||
No Prescription » Prescription Drugs 17 » Voltaren Cataflam Voltaren is used for: Treating pain redness swelling and sensitivity to light which are symptoms related to certain eye surgeries. Diclofenac is in a group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Diclofenac works by reducing hormones that cause inflammation and pain in the body. Diclofenac is used to treat pain or inflammation caused by arthritis or ankylosing spondylitis. Nonsteroidal anti-inflammatory drugs (also called NSAIDs) are used to relieve some symptoms caused by arthritis (rheumatism) such as inflammation swelling stiffness and joint pain. Treatment of Rheumatoid arthritis Osteoarthritis Pain especially due to inflammation (eg period pain)Local pain and inflammation in soft tissues. Buy Voltaren Cataflam and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Voltaren Cataflam: Product Type: Prescription Drugs 17 Voltaren ( Cataflam Generic Diclofenac ) Voltaren (Cataflam Generic Diclofenac) Cataflam Generic Diclofenac 25mg Cataflam Generic Diclofenac Voltaren
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
